Hyperpolarized (HP) gas magnetic resonance imaging (MRI) of the lungs offers additional information that cannot be obtained with CT scan, the current gold standard for imaging this disorder. As a nonionizing technique, MRI is an ideal modality for pulmonary imaging; in particular in the infant and pediatric population. Nevertheless, due to the low proton density of the lung parenchyma (only
20% that of solid tissues), numerous air-tissue interfaces that lead to rapid signal decay, and cardiac and respiratory sources of motion that further degrade image quality , MRI has played a limited role in the evaluation of lung pathologies. In this setting, HP gas (using 129Xe) MRI may play a role in helping determine the regional distribution of alveolar sizes, partial pressure of oxygen, alveolar wall thickness, and gas transport efficiency of the microvasculature within the lungs of infants with a diagnosis of bronchopulmonary dysplasia (BPD).

开始日期2026-08-01

申办/合作机构

Xemed LLC

[+1]

NCT06351345

/ Not yet recruiting临床2期IIT

129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

开始日期2025-05-01

申办/合作机构

Duke University

[+1]

NCT06853145

/ Not yet recruiting早期临床1期IIT

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

开始日期2025-03-01

申办/合作机构

University of Virginia

100 项与氙[129Xe] 相关的临床结果

登录后查看更多信息

100 项与氙[129Xe] 相关的转化医学

登录后查看更多信息

100 项与氙[129Xe] 相关的专利（医药）

登录后查看更多信息

3,087

项与氙[129Xe] 相关的文献（医药）

2025-04-01·MAGNETIC RESONANCE IN MEDICINE

Evaluation of an integrated variable flip angle protocol to estimate coil B₁ for hyperpolarized MRI

Article

作者: Ng, Kher Lik ; Shinozaki, Ayaka ; Zaccagna, Fulvio ; Axford, Aaron ; McIntyre, Anthony ; Berner, Lise ; Durrant, Marianne ; Ravetz, Zack ; Schulte, Rolf F. ; Ricchi, Mattia ; Lewis, Andrew J. M. ; Sgambelluri, Noemi ; Jacob, Kenneth ; Rider, Oliver J. ; Tyler, Damian J. ; Rayner, Jennifer J. ; Grist, James T. ; Birkhoelzer, Sarah ; Mills, Rebecca ; Yeung, Kylie ; Gleeson, Fergus V. ; McGing, Jordan J.

Abstract:

Purpose:

The purpose of this work is to validate a simple and versatile integrated variable flip angle (VFA) method for mapping B1 in hyperpolarized MRI, which can be used to correct signal variations due to coil inhomogeneity.

Theory and Methods:

Simulations were run to assess performance of the VFA B1 mapping method compared to the currently used constant flip angle (CFA) approach. Simulation results were used to inform the design of VFA sequences, validated in four volunteers for hyperpolarized xenon‐129 imaging of the lungs and another four volunteers for hyperpolarized carbon‐13 imaging of the human brain. B1 maps obtained were used to correct transmit and receive inhomogeneity in the images.

Results:

Simulations showed improved performance of the VFA approach over the CFA approach with reduced sensitivity to T1. For xenon‐129, the B1 maps accurately reflected the variation of signal depolarization, but in some cases could not be used to correct for coil receive inhomogeneity due to a lack of transmit‐receive reciprocity resulting from suboptimal coil positioning. For carbon‐13, the B1 maps showed good agreement with a separately acquired B1 map of a phantom and were effectively used to correct coil‐induced signal inhomogeneity.

Conclusion:

A simple, versatile, and effective VFA B1 mapping method was implemented and evaluated. Inclusion of the B1 mapping method in hyperpolarized imaging studies can enable more robust signal quantification.

2025-03-01·JOURNAL OF MOLECULAR LIQUIDS

Probing the organization of liquids using 129Xe NMR spectroscopy III: Linear hydrogenated and fluorinated alcohols

作者: Morgado, Pedro ; Eusebio, Tiago M. ; Martins, Luis F. G. ; Filipe, Eduardo J. M.

The liquid organization of six alcs. (CH₃(CH₂)_nOH, n = 1, 2, 3, 5, 7, 9) and five fluorinated alcs. (CF₃(CF₂)_nCH₂OH, n = 1, 2, 3, 4, 5) was studied using ¹²⁹Xe as an NMR probe.For the first time, spectra were obtained as a function of temperature to allow the comparison of the different solvents at similar thermodn. conditions.Correlations of the xenon medium shifts as a function of group d. were obtained, assessing the relative interactivity of the different groups forming the solvent mols.Mol. dynamics simulations confirm and complement the mol. interpretations obtained from the NMR results.It is shown that xenon is not randomly distributed throughout the liquid, but preferentially located near the aliphatic end of the solvent mols., resulting in an enrichment of CH₃ and CF₃ groups around xenon.Conversely, xenon′s coordination sphere is depleted in CH₂OH groups relatively to the stoichiometric proportion.This work extends to n-alkanols and 1H,1H-perfluoroalkanols the methodol. previously applied to n-alkanes, perfluoroalkanes and perfluoroalkylalkanes, allowing the prediction of the ¹²⁹Xe medium shift in all these solvents, at any temperature, providing the d. is known.The advantages of using xenon as an NMR probe are clearly demonstrated.The high sensitivity of the xenon atom provides detailed information on the nature, d. and organization of the solvent′s chem. groups within its coordination sphere.

2025-02-18·ANALYTICAL CHEMISTRY

Continuous Delivery of Hyperpolarized Xenon-129 Gas Using a “Stopped-Flow” Clinical-Scale Cryogen-Free Hyperpolarizer

Article

作者: Dmochowski, Ivan J. ; Asif, Faisal ; Ahmed, Firoz ; Chekmenev, Eduard Y. ; Ariyasingha, Nuwandi M. ; Gyesi, Joseph ; Barlow, Michael J. ; Oladun, Clementinah ; Nikolaou, Panayiotis ; Abdurraheem, Abubakar ; Goodson, Boyd M. ; Shcherbakov, Anton ; Rudman, Nathan A. ; Chowdhury, Md Raduanul H.

In 2022, the FDA approved hyperpolarized (HP) ¹²⁹Xe gas as an inhalable contrast agent for functional lung imaging. For clinical imaging, HP ¹²⁹Xe is usually given as a bolus inhalation. However, for preclinical applications (e.g., pulmonary imaging in small rodents), the continuous delivery of HP ¹²⁹Xe is greatly desired to enable MRI scanning under conditions of physiological continuous animal breathing patterns. Moreover, HP ¹²⁹Xe gas can be utilized for other applications including materials science and bioanalytical chemistry, where a continuous flow of hyperpolarized gas through an NMR sample over several minutes is also desired for sensing of ¹²⁹Xe inside an NMR spectrometer. ¹²⁹Xe is often hyperpolarized using continuous-flow spin-exchange optical pumping, which employs a lean (1-2%) mixture of Xe and a carrier gas (e.g., He and N₂). The low Xe concentration in the produced output reduces the NMR detection sensitivity, and thus, Xe cryo-collection is typically employed to achieve near-100% pure gas-phase Xe before administration to the sample or subject. However, the need for cryo-collection undermines a key advantage of continuous-flow production, i.e., the continuous flowing in a hyperpolarizer HP ¹²⁹Xe gas is trapped inside the hyperpolarizer, and the produced HP ¹²⁹Xe gas is released at once when the production cycle (30-60 min) is completed. An alternative HP ¹²⁹Xe production technology employs a "stopped-flow" approach, where a batch of HP gas is hyperpolarized over time and quickly released from a hyperpolarizer. Here, a clinical-scale "stopped-flow" ¹²⁹Xe hyperpolarizer was employed to hyperpolarize a 1.3 L-atm batch of 50:50 Xe:N₂ gas mixture inside a glass cell with an ultralong lifetime of the HP ¹²⁹Xe state (T₁ > 2 h). The produced HP ¹²⁹Xe gas was slowly delivered into a 5 mm NMR tube via PEEK tubing under a wide range of gas flow rates: 3-180 standard cubic centimeters per minute (sccm). The polarization of the gas ejected from the hyperpolarizer was quantified using in situ low-field NMR polarimetry and additionally verified using a 0.35 T clinical MRI scanner. Continuous-flow delivery of HP ¹²⁹Xe was demonstrated for up to 15 min with a gas flow rate of 45-150 sccm over a 2.5-m length of PEEK tubing, suffering only small losses in ¹²⁹Xe polarization. These observations are additionally supported by ¹²⁹Xe relaxation measurements inside the PEEK tubing employed for gas delivery and the 5 mm NMR tube employed for polarimetry. ¹²⁹Xe polarization of 16-19% was obtained in the delivered gas, starting with an "in-polarizer" ¹²⁹Xe polarization of 19%. We envision that this method can be employed for on-demand cryogen-free delivery of hyperpolarized gas using "stopped-flow" ¹²⁹Xe hyperpolarizers for a broad range of applications, from preclinical imaging to biosensors, and to spectroscopy of materials surfaces.

项与氙[129Xe] 相关的新闻（医药）

2024-11-26

·PRNewswire

Long COVID Brain Fog Linked to Lung Function

CHICAGO, Nov. 26, 2024 /PRNewswire/ -- In patients with long COVID, lower pulmonary gas exchange may be associated with impaired cognitive function, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). According to the National Center for Health Statistics, approximately 17.6% of adults in the U.S. have experienced a post-COVID condition commonly referred to as long COVID. People with long COVID may exhibit a wide variety of symptoms, including difficulty concentrating ("brain fog"), change in sense of smell or taste, fatigue, joint or muscle pain, dyspnea (shortness of breath), digestive symptoms, and more. These symptoms may persist for weeks, months, or even years after COVID-19 infection. Researchers from the University of Iowa in Iowa City set out to assess associations between pulmonary MRI gas exchange, structural and functional brain MRI, and cognition in long COVID patients. In pulmonary gas exchange, oxygen moves from the lungs to the bloodstream, while carbon dioxide moves from the bloodstream to the lungs. "This is the first time that MRI has been used to jointly assess lung and brain function to investigate their relationship in long COVID," said the study's lead author Keegan Staab, B.S., graduate research assistant in the Department of Radiology at the University of Iowa in Iowa City. "This research is new in that it combines multiple unique imaging types to study a multiorgan relationship in a disease population." Senior study author Sean B. Fain, Ph.D., professor and vice chair for research in the Department of Radiology at the University of Iowa, added, "If these findings can be generalized to the long COVID population, the study suggests that there may be a causative relationship between cognitive dysfunction and lung dysfunction, suggesting a potential treatment strategy using methods that target improved gas exchange." For the study, 10 female and 2 male patients (median age: 59 years) who had persistent dyspnea and/or fatigue following the resolution of acute COVID-19 infection were recruited from a post-COVID-19 clinic. Hyperpolarized Xe pulmonary MRI, structural and functional brain MRI, pulmonary function tests and cognitive tests were acquired. "129Xe MRI allows for advanced measurements of ventilation and gas exchange," Staab said. "The literature also indicates that 129Xe may be more sensitive to pulmonary injury compared to standard breathing tests, making it better suited to study long COVID in which patients typically have normal breathing tests." Perceived cognitive difficulties were measured using Patient-Reported Outcomes Measurement Information System, and objective cognitive performance was assessed using the National Institutes of Health Toolbox V3 Cognition Battery. "There was a range of cognitive difficulties among the patients in the study," Staab said. "Some were mild and indicated slight dysfunction, while others were more serious and indicated that some patients have slow thinking and trouble concentrating several times per day." The results showed that lower pulmonary gas exchange may be associated with cognitive dysfunction, as well as lower gray matter and white matter volumes in patients with long COVID. In addition, the researchers observed significant relationships suggesting that increased cerebral blood flow is associated with decreased gas exchange in long COVID patients. Staab said larger studies are needed to investigate the association between gas exchange and cerebral blood flow in long COVID. "This relationship could be a compensatory mechanism where lower lung function is compensated by higher cardiac output and higher brain perfusion," he said. "It's also a possibility that the disease mechanism that impairs pulmonary gas exchange also leads to higher brain perfusion through downstream vascular injury in both lung and brain." Based on the findings of this study, gas exchange abnormalities may help identify long COVID patients who require additional treatment or long-term management. Other co-authors are Marrissa J. McIntosh, Ph.DDD., Jonathan L. Percy, B.S., Andrew D. Hahn, Ph.DDD., Natally AlArab, M.D., Conner J. Wharff, B.S. B.A. RT(R)(MR), Eric Bruening, M.S., Alejandro P. Comellas, M.D., Eric A. Hoffman, Ph.DDD., Carinda Linkenmeyer, M.A.E., Tara Lanning, B.S., and Karin F. Hoth, Ph.DDD. Note: Copies of RSNA 2024 news releases and electronic images will be available online at RSNA.org/press24. RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org) For patient-friendly information on MRI, visit RadiologyInfo.org. SOURCE Radiological Society of North America (RSNA) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

2024-05-08

·BioSpace

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence

DURHAM, NC and LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, has been selected as one of the featured companies and a poster presenter at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS), a testament to the value of our XENOVIEW technology seen across lung clinicians and pulmonary drug developers. The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego. The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians. After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd. Visit booth #2813 to engage directly with our executive team, including Christopher von Jako, PhD, Chief Executive Officer; Alex Dusek, Chief Commercial Officer; and Kiarash Emami, PhD, VP of Technology & Applications. Discover firsthand how Polarean strives to revolutionize pulmonary medicine through direct visualization of lung ventilation as we share detailed insights, forge valuable connections, and collaborate to shape the future of lung imaging. This year, the breadth of Xenon MRI research and the number of displays outpaced all previous years, with 33 presentations from 10 different sites and multiple categories, including asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, hematopoietic stem cell transplant, lung cancer resection, radiation-induced lung injury, pulmonary arterial hypertension, and thoracic insufficiency syndrome. Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships. These events provide an unparalleled opportunity to elevate awareness of our technology among clinicians, regulators, investors, and potential pharmaceutical industry partners. As we strive to advance our commercialization strategy, the increase in Xenon MRI posters and presentations marks significant strides in amplifying understanding and enthusiasm for Xenon MRI and the spectrum of therapeutic disciplines that could benefit from our technology.” See the listing below for details on the presentation title, abstract number, session time, and location. XENOVIEW IMPORTANT SAFETY INFORMATION Indication XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. Limitations of Use XENOVIEW has not been evaluated for use with lung perfusion imaging. CONTRAINDICATIONS None. Warnings and Precautions Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. Adverse Reactions Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age. Please see full prescribing information at About Polarean ( ) Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit . About The American Thoracic Society ( ) The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. ATS Abstract Title Presentation Date Abstract Number Session and Location Hyperpolarized 129Xe MRI: What Additional Information Does It Provide? May 18, 2024 3:10 PM - 3:50 PM Session PG16 San Diego Convention Center, Room 6D (UpperLevel) Quantifying the Impact of Cannabis Smoking in Lungs of Young Adults Using CT and Xe MRI May 19, 2024 9:15 AM - 11:15 AM 1014 Session A29 San Diego Convention Center, Room 6E (UpperLevel) Six-month Longitudinal Changes in129-XE and HRCT Imaging Metrics Tend to Associate With On-study COPD Exacerbations May 19, 2024 9:15 AM - 11:15 AM 1017 Session A29 San Diego Convention Center, Room 6E (UpperLevel) Advanced 4D Hyperpolarized Gas Imaging of Ventilation and Dissolved Gas Biomarkers in COPD May 19, 2024 9:15 AM - 11:15 AM 1016 Session A29 San Diego Convention Center, Room 6E (UpperLevel) 3-month Change in Hyperpolarized Xe MRI Membrane Uptake Predicts 6-month Change in Lung Function in Patients With Idiopathic Pulmonary Fibrosis May 19, 2024 11:30 AM - 1:15 PM P862 Session A47 San Diego Convention Center, Area H (Hall H,Ground Level) Using Xenon MRI to Evaluate the Trajectories of Idiopathic Pulmonary Fibrosis May 19, 2024 2:15 PM - 4:15 PM 914 Session A104 San Diego Convention Center, Room 33A-C(Upper Level) Combining Hyperpolarized Xe MR Imagingand Spectroscopy to Estimate Pulmonary Vascular Resistance May 19, 2024 3:39 PM - 3:51 PM Session A97 San Diego Convention Center, Room 6D (UpperLevel) Magnetic Resonance Imaging Ventilation Phenotypes of Severe Asthma May 19, 2024 3:39 PM - 3:51 PM Session A99 Marriott Marquis San Diego Marina, PacificBallroom 24-26 (Ground Floor, North Tower) Success and Feasibility of MultipleBreath Washout: Prospective Multi-center Results From the Transpire Study May 20, 2024 9:15 AM - 11:15 AM 421 Session B25 San Diego Convention Center, Room 25A-C(Upper Level) Improved Quantification of Ventilation Heterogeneity in Hyperpolarized Xenon MRI Using Physics-rooted Bias-field Correction May 20, 2024 11:30 AM - 1:15 PM P170 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Addressing Healthy Aging Variations in Ventilation From Childhood to Older Age Using Xenon MRI May 20, 2024 11:30 AM - 1:15 PM P171 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Assessing Radiation-induced Lung Injury Using a Chemical Shift Imaging-based CSSR Technique May 20, 2024 11:30 AM - 1:15 PM P176 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Sex and Age-dependence of Xe MRI Cardiopulmonary Oscillations in Healthy Volunteers May 20, 2024 11:30 AM - 1:15 PM P188 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Estimating Physiological Values of Membrane and Red Blood Cell Conductance Using Xe Gas Exchange MRI May 20, 2024 11:30 AM - 1:15 PM P187 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Increased BMI Is Associated With Elevated Membrane Uptake on Xe Gas Exchange MRI in Healthy Subjects May 20, 2024 11:30 AM - 1:15 PM P178 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Establishing a Standardized Healthy Reference Distribution for Multi-site Xe Gas Exchange MRI Across Major Scanner Platforms May 20, 2024 11:30 AM - 1:15 PM P172 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Quantifying Spatial Distribution of Ventilation Defects in Lung Imaging With Hyperpolarized Xenon MRI May 20, 2024 11:30 AM - 1:15 PM P174 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) Assessment of Gas Exchange WithHyperpolarized Xe MR Imaging in Mild Asthmatics When Administered a Vasodilator May 20, 2024 11:30 AM - 1:15 PM P190 Session B80-1 San Diego Convention Center, Area B (Hall A-B2,Ground Level) 129Xe MRI With Optimized Bias Field Correction to Assess Ventilation Gradients in Individuals With Normal Lung Function May 20, 2024 11:30 AM - 1:15 PM P701 Session B80-2 Research and Clinical Applications of Hyperpolarized 129Xe MRI May 20, 2024 3:00 PM - 3:15 PM Session B91 San Diego Convention Center, Room 24A-C(Upper Level) Assessment of Obstructive and Restrictive Lung Disease Via MRI in Bronchopulmonary Dysplasia Patients May 21, 2024 9:15 AM - 11:15 AM 404 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Changes in Individual Ventilation Defects in Cystic Fibrosis After Initiation of Modulator Therapy, in the Hypoint Trial May 21, 2024 9:15 AM - 11:15 AM 405 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Xe MRI and Oscillometry Evidence ofImproved Small Airways Dysfunction After 6-weeks ICS/LABA/LAMA Therapy in Moderate Asthma May 21, 2024 9:15 AM - 11:15 AM 407 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Comparison of CT-based Measurements of Ventilation and Perfusion to Ventilation and Gas Exchange Measurements From Hyperpolarized Xe MRI May 21, 2024 9:15 AM - 11:15 AM 410 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) CT Mucus Score Predicts Response to 6-weeks ICS/LABA/LAMA in Moderate Asthma May 21, 2024 9:15 AM - 11:15 AM 413 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Xe MR Evidence of Abnormal Gas-exchange in Mild-moderate and Severe Asthma May 21, 2024 9:15 AM - 11:15 AM 418 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Ventilation Defect Burden Quantified byTechnegas SPECT and Xe MRI Predicts Lung Cancer Resection Outcomes May 21, 2024 9:15 AM - 11:15 AM 420 Session C29 San Diego Convention Center, Room 25A-C(Upper Level) Rapid and Persistent 6-week Responseto ICS/LABA/LAMA in Mild-moderate Asthma May 21, 2024 11:30 AM - 1:15 PM P690 Session C71 San Diego Convention Center, Area F (Hall A-B2,Ground Level) Evaluation of Xenon Gas Phase and Dissolved Phase Delays Using Dynamic 129Xe-hyperpolarized MRI in Pre-clinical Thoracic Insufficiency Syndrome Model May 21, 2024 11:30 AM - 1:15 PM P156 Session C73 San Diego Convention Center, Area F (Hall A-B2,Ground Level) Xe MRI Reveals Regional Gas-exchange Abnormalities in Cystic Fibrosis Lung Disease May 21, 2024 11:30 AM - 1:15 PM P174 Session C74 San Diego Convention Center, Area F (Hall A-B2,Ground Level) Quantitative Characterization of Regional Ventilation and Perfusion in Patients With Persistent COVID-19 Symptoms Using Hyperpolarized Xe MRI and Dual Energy CT May 21, 2024 11:30 AM - 1:15 PM P186 Session C75 San Diego Convention Center, Area F (Hall A-B2,Ground Level) The EXPLAIN (Hyperpolarised Xenon Magnetic Resonance Pulmonary Imaging in Patients With Long-COVID) Study: The Primary Outcome May 21, 2024 11:30 AM - 1:15 PM P195 Session C75 San Diego Convention Center, Area F (Hall A-B2,Ground Level) Same-day and Six-week Repeatability of Hyperpolarized Xe MRI Measures in Patients With Pulmonary Arterial Hypertension May 22, 2024 11:00 AM - 1:00 PM 306 Session D109 San Diego Convention Center, Room 28C-E(Upper Level) Contact Information: Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@polarean.com Polarean Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@wallbrookpr.com Polarean Media Contact: Alexis Opp +1 (919) 206-7900 aopp@polarean.com General inquiries: info@polarean.com Follow Polarean on LinkedIn here Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@polarean.com Polarean Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@wallbrookpr.com Polarean Media Contact: Alexis Opp +1 (919) 206-7900 aopp@polarean.com General inquiries: info@polarean.com

放射疗法

2023-08-03

·BioSpace

Polarean Receives Clearance for New MRI Chest CoilAdditional clearance for new MRI chest coil further supports the recently announced collaboration with Philips.

Durham, NC, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced MRI scanning of the lungs, announces it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s specialized MRI chest coil to now include Philips 3.0T MRI scanners for the visualization of the Xenon-129 (129Xe) nuclei. The Polarean XENOVIEW™ 3.0T Chest Coil is a flexible, single channel, transmit-receive RF coil tuned to image 129Xe nuclei while a patient is positioned inside a multinuclei-capable MRI scanner. The XENOVIEW Chest Coil is indicated to be used in conjunction with compatible 3.0T MRI scanners and approved hyperpolarized 129Xe for oral inhalation for the evaluation of lung ventilation in adults and pediatric patients, aged 12 years and older. The addition of the new Philips configuration does not affect the intended use of the device; the safety and effectiveness has been confirmed with testing. Christopher von Jako, CEO of Polarean, said: “Polarean continues to develop and launch new devices and accessories that empower sites to perform modern respiratory imaging, enabling as many clinicians as possible to use our technology for their patients. This FDA clearance also further supports our recently announced collaboration with Philips, by expanding our product line to be compatible with their advanced MRI systems.” About Polarean ( ) The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean’s vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. The company also commercializes systems (such as the HPX hyperpolarization system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations. Contacts: Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@polarean.com Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@wallbrookpr.com Media Contact: Director of Marketing & Logistics Michelle Caissie +1 (919) 206-7900, ext. 136 mcaissie@polarean.com POL-PR-2309 Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@polarean.com Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@wallbrookpr.com Media Contact: Michelle Caissie Director of Marketing & Logistics +1 (919) 206-7900, ext. 136 mcaissie@polarean.com

100 项与氙[129Xe] 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
造影剂	美国	Polarean, Inc.	2022-12-23
肺部疾病	美国	Polarean, Inc.	2022-12-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结缔组织病	临床2期	美国	American Heart Association, Inc.	2024-08-12
结缔组织病	临床2期	美国	Duke University	2024-08-12
与结缔组织病相关的肺动脉高压	临床2期	美国	American Heart Association, Inc.	2024-08-12
与结缔组织病相关的肺动脉高压	临床2期	美国	Duke University	2024-08-12
贫血	临床2期	美国	National Institutes of Health	2024-01-12
慢性血栓栓塞性肺动脉高压	临床2期	美国	National Institutes of Health	2024-01-12
呼吸困难	临床2期	美国	National Institutes of Health	2024-01-12
间质性肺疾病	临床2期	美国	National Institutes of Health	2024-01-12
红细胞增多症	临床2期	美国	National Institutes of Health	2024-01-12
肺栓塞	临床2期	美国	National Institutes of Health	2024-01-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03417687 (CTgov)	临床3期	肺部疾病	38	129Xe MRI	觸築製願齋願艱憲簾願(願膚積憲鬱鬱淵齋鹹壓) = 糧範醖鹽餘壓鬱艱窪範顧膚顧鏇觸糧鬱膚糧蓋 (願範鏇艱淵鏇鹹鹽簾憲, 2.88)	-	2022-06-28
ASTRO2020	N/A	-	-	Hyperpolarized 129 Xe (Gas exchange-optimized plans)	襯夢膚製獵齋蓋獵築簾(糧衊製選醖廠壓鹽積夢) = 壓積鏇蓋餘憲鏇廠製簾選網夢築憲齋鏇顧蓋鏇 (構夢鹹淵夢鑰遞製窪衊, 45) 更多	-	2020-11-01
				Hyperpolarized 129 Xe (Ventilation-optimized plans)	襯夢膚製獵齋蓋獵築簾(糧衊製選醖廠壓鹽積夢) = 餘遞糧鹹膚衊鬱製積淵選網夢築憲齋鏇顧蓋鏇 (構夢鹹淵夢鑰遞製窪衊, 31) 更多
ERS2019	N/A	间质性肺疾病	33	Hyperpolarised 129-xenon	淵願窪範鏇觸廠選艱簾(鹽襯製顧鬱憲窪選糧齋) = 網淵壓繭遞製窪壓糧壓膚築鑰膚醖網糧廠範窪 (醖鹹遞艱選願淵襯繭構 )	-	2019-09-28
				Hyperpolarised 129-xenon	淵願窪範鏇觸廠選艱簾(鹽襯製顧鬱憲窪選糧齋) = 繭廠願鏇範簾膚窪鹽繭膚築鑰膚醖網糧廠範窪 (醖鹹遞艱選願淵襯繭構 ) 更多